alogliptin and actoplus met — Competitive Intelligence Brief

alogliptin and actoplus met (alogliptin and actoplus met) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor + biguanide combination. Area: Diabetes.

marketed DPP-4 inhibitor + biguanide combination DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule

Target snapshot

alogliptin and actoplus met (alogliptin and actoplus met) — The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
alogliptin and actoplus met TARGET	alogliptin and actoplus met	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
DPP-4 inhibitor + metformin group	DPP-4 inhibitor + metformin group	Beni-Suef University	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
Saxagliptin plus metformin IR	Saxagliptin plus metformin IR	AstraZeneca	phase 3	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin (AMPK pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor + biguanide combination class)

1. AstraZeneca · 2 drugs in this class
2. Baylor College of Medicine · 1 drug in this class
3. Beni-Suef University · 1 drug in this class
4. The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 1 drug in this class